A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor

Molecular and Cellular Biology

Volumn 27, Issue 7, 2007, Pages 2590-2600

  Menendez, Daniel ^a   Inga, Alberto ^b   Snipe, Joyce ^a   Krysiak, Oliver ^c   Schönfelder, Gilbert ^c   Resnick, Michael A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF GENOA   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; ESTROGEN RECEPTOR; PROTEIN P53; THYMINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIGAND BINDING; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REGULATORY SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

BINDING SITES; CELL LINE, TUMOR; DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; LIGANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 34147204571     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01742-06     Document Type: Article

References (60)

1. Anolik, J. H., C. M. Klinge, R. Hilf, and R. A. Bambara. 1995. Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. Biochemistry 34:2511-2520.
2. Bando, H., H. A. Weich, M. Brokelmann, S. Horiguchi, N. Funata, T. Ogawa, and M. Toi. 2005. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br. J. Cancer 92:553-561.
3. Blagosklonny, M. V., W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273:11995-11998.
4. Bond, G. L., W. Hu, E. E. Bond, H. Robins, S. G. Lutzker, N. C. Arva, J. Bargonetti, F. Bartel, H. Taubert, P. Wuerl, K. Onel, L. Yip, S. J. Hwang, L. C. Strong, G. Lozano, and A. J. Levine. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
5. Carmeliet, P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3):4-10.
6. Cartharius, K., K. Frech, K. Grote, B. Klocke, M. Haltmeier, A. Klingenhoff, M. Frisch, M. Bayerlein, and T. Werner. 2005. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21:2933-2942.
7. Cawley, S., S. Bekiranov, H. H. Ng, P. Kapranov, E. A. Sekinger, D. Kampa, A. Piccolboni, V. Sementchenko, J. Cheng, A. J. Williams, R. Wheeler, B. Wong, J. Drenkow, M. Yamanaka, S. Patel, S. Brubaker, H. Tammana, G. Helt, K. Struhl, and T. R. Gingeras. 2004. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116:499-509.
8. Chen, W. S., R. P. Kitson, and R. H. Goldfarb. 2002. Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1). In Vivo 16:439-445.
9. Driscoll, M. D., G. Sathya, M. Muyan, C. M. Klinge, R. Hilf, and R. A. Bambara. 1998. Sequence requirements for estrogen receptor binding to estrogen response elements. J. Biol. Chem. 273:29321-29330.
10. el-Deiry, W. S., S. E. Kern, J. A. Pietenpol, K. W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
11. Espinosa, J. M., and B. M. Emerson. 2001. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8:57-69.
12. Fan, F., J. S. Wey, M. F. MeCarty, A. Belcheva, W. Liu, T. W. Bauer, R. J. Somcio, Y. Wu, A. Hooper, D. J. Hicklin, and L. M. Ellis. 2005. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647-2653.
13. Ferrara, N., H. P. Gerber, and J. LeCouter. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-676.
14. Fong, G. H., J. Rossant, M. Gertsenstein, and M. L. Breitman. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70.
15. Goldman, C. K., R. L. Kendall, G. Cabrera, L. Soroceanu, Y. Heike, G. Y. Gillespie, G. P. Siegal, X. Mao, A. J. Bett, W. R. Huckle, K. A. Thomas, and D. T. Curiel. 1998. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA 95:8795-8800.
16. Gruber, C. J., D. M. Gruber, I. M. Gruber, F. Wieser, and J. C. Huber. 2004. Anatomy of the estrogen response element. Trends Endocrinol. Metab. 15:73-78.
17. Hahn, D., R. Simak, G. E. Steiner, A. Handisurya, M. Susani, and M. Marberger. 2000. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues. J. Urol. 164:506-510.
18. Hallikas, O., K. Palin, N. Sinjushina, R. Rautiainen, J. Partanen, E. Ukkonen, and J. Taipale. 2006. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. Cell 124:47-59.
19. Hearnes, J. M., D. J. Mays, K. L. Schavolt, L. Tang, X. Jiang, and J. A. Pietenpol. 2005. Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol. Cell. Biol. 25:10148-10158.
20. Hornig, C., and H. A. Weich. 1999. Soluble VEGF receptors. Angiogenesis 3:33-39.
21. Inga, A., F. Storici, T. A. Darden, and M. A. Resnick. 2002. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell. Biol. 22:8612-8625.
22. Ito, M., C. X. Yuan, S. Malik, W. Gu, J. D. Fondell, S. Yamamura, Z. Y. Fu, X. Zhang, J. Qin, and R. G. Roeder. 1999. Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol. Cell 3:361-370.
23. Kang, Y. K., M. Guermah, C. X. Yuan, and R. G. Roeder. 2002. The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc. Natl. Acad. Sci. USA 99:2642-2647.
24. Kaplan, R. N., R. D. Riba, S. Zacharoulis, A. H. Bramley, L. Vincent, C. Costa, D. D. MacDonald, D. K. Jin, K. Shido, S. A. Kerns, Z. Zhu, D. Hicklin, Y. Wu, J. L. Port, N. Altorki, E. R. Port, D. Ruggero, S. V. Shmelkov, K. K. Jensen, S. Rafii, and D. Lyden. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
25. Kearney, J. B., C. A. Ambler, K. A. Monaco, N. Johnson, R. G. Rapoport, and V. L. Bautch. 2002. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 99:2397-2407.
26. Kendall, R. L., and K. A. Thomas. 1993. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90:10705-10709.
27. Kendall, R. L., G. Wang, and K. A. Thomas. 1996. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem. Biophys. Res. Commun. 226: 324-328.
28. Klein-Hitpass, L., M. Kaling, and G. U. Ryffel. 1988. Synergism of closely adjacent estrogen-responsive elements increases their regulatory potential. J. Mol. Biol. 201:537-544.
29. Klein-Hitpass, L., G. U. Ryffel, E. Heitlinger, and A. C. Cato. 1988. A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res. 16:647-663.
30. Klinge, C. M. 2001. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29:2905-2919.
31. Krysiak, O., A. Bretschneider, E. Zhong, J. Webb, H. Hopp, S. Verlohren, N. Fuhr, M. Lanowska, A. Nonnenmacher, R. Vetter, J. Jankowski, M. Paul, and G. Schonfelder. 2005. Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF. Circ. Res. 97:1253-1261.
32. Laptenko, O., and C. Prives. 2006. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13:951-961.
33. Lin, P., S. Sankar, S. Shan, M. W. Dewhirst, P. J. Polverini, T. Q. Quinn, and K. G. Peters. 1998. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. 9:49-58.
34. Liu, G., J. A. Schwartz, and S. C. Brooks. 2000. Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res. 60:1810-1814.
35. Liu, G., J. A. Schwartz, and S. C. Brooks. 1999. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 264:359-364.
36. Liu, W., S. D. Konduri, S. Bansal, B. K. Nayak, S. A. Rajasekaran, S. M. Karuppayil, A. K. Rajasekaran, and G. M. Das. 2006. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J. Biol. Chem. 281:9837-9840.
37. Lyden, D., K. Hattori, S. Dias, C. Costa, P. Blaikie, L. Butros, A. Chadburn, B. Heissig, W. Marks, L. Witte, Y. Wu, D. Hicklin, Z. Zhu, N. R. Hackett, R. G. Crystal, M. A. Moore, K. A. Hajjar, K. Manova, R. Benezra, and S. Rafii. 2001. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:1194-1201.
38. Malik, S., and R. G. Roeder. 2000. Transcriptional regulation through Mediator-like coactivators in yeast and metazoan cells. Trends Biochem. Sci. 25:277-283.
39. Masood, R., J. Cai, T. Zheng, D. L. Smith, D. R. Hinton, and P. S. Gill. 2001. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913.
40. Matys, V., E. Fricke, R. Geffers, E. Gossling, M. Haubrock, R. Hehl, K. Hornischer, D. Karas, A. E. Kel, O. V. Kel-Margoulis, D. U. Kloos, S. Land, B. Lewicki-Potapov, H. Michael, R. Munch, I. Reuter, S. Rotert, H. Saxel, M. Scheer, S. Tbiele, and E. Wingender. 2003. TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 31:374-378.
41. Menendez, D., O. Krysiak, A. Inga, B. Krysiak, M. A. Resnick, and G. Schonfelder. 2006. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc. Natl. Acad. Sci. USA 103:1406-1411.
42. O'Lone, R., M. C. Frith, E. K. Karlsson, and U. Hansen. 2004. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 18:1859-1875.
43. Prives, C., and P. A. Hall. 1999. The p53 pathway. J. Pathol. 187:112-126.
44. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34-44.
45. Resnick, M. A., and A. Inga. 2003. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl. Acad. Sci. USA 100:9934-9939.
46. Roeckl, W., D. Hecht, H. Sztajer, J. Waltenberger, A. Yayon, and H. A. Weich. 1998. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2. Exp. Cell Res. 241:161-170.
47. Sako, A., J. Kitayama, H. Koyama, H. Ueno, H. Uchida, H. Hamada, and H. Nagawa. 2004. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. Cancer Res. 64:3624-3628.
48. Shibuya, M., and L. Claesson-Welsh. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 312:549-560.
49. Tokino, T., S. Thiagalingam, W. S. el-Deiry, T. Waldman, K. W. Kinzler, and B. Vogelstein. 1994. p53 tagged sites from human genomic DNA. Hum. Mol. Genet. 3:1537-1542.
50. Tomso, D. J., A. Inga, D. Menendez, G. S. Pittman, M. R. Campbell, F. Storici, D. A. Bell, and M. A. Resnick. 2005. Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc. Natl. Acad. Sci. USA 102:6431-6436.
51. Velculescu, V. E., and W. S. El-Deiry. 1996. Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem. 42:858-868.
52. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
53. von Marschall, Z., T. Cramer, M. Hocker, R. Burde, T. Plath, M. Schirner, R. Heidenreich, G. Breier, E. O. Riecken, B. Wiedenmann, and S. Rosewicz. 2000. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 119:1358-1372.
54. Vyhlidal, C., I. Samudio, M. P. Kladde, and S. Safe. 2000. Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. J. Mol. Endocrinol. 24:329-338.
55. Wei, C. L., Q. Wu, V. B. Vega, K. P. Chiu, P. Ng, T. Zhang, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, J. Liu, X. D. Zhao, J. L. Chew, Y. L. Lee, V. A. Kuznetsov, W. K. Sung, L. D. Miller, B. Lim, E. T. Liu, Q. Yu, H. H. Ng, and Y. Ruan. 2006. A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207-219.
56. Yap, N., C. L. Yu, and S. Y. Cheng. 1996. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc. Natl. Acad. Sci. USA 93:4273-4277.
57. Yu, C. L., P. Driggers, G. Barrera-Hemandez, S. B. Nunez, J. H. Segars, and S. Cheng. 1997. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun. 239:617-620.
58. Zhang, L., D. Yu, M. Hu, S. Xiong, A. Lang, L. M. Ellis, and R. E. Pollock. 2000. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60:3655-3661.
59. Zhang, X., A. Krutchinsky, A. Fukuda, W. Chen, S. Yamamura, B. T. Chait, and R. G. Roeder. 2005. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol. Cell 19:89-100.
60. Zhao, Z., Y. X. Fu, D. Hewett-Emmett, and E. Boerwinkle. 2003. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene 312:207-213.